202 related articles for article (PubMed ID: 35410028)
1. A Scoping Review of Galectin-3 as a Biomarker of Cardiovascular Diseases in Pediatric Populations.
Smereczyńska-Wierzbicka E; Pietrzak R; Werner B
Int J Environ Res Public Health; 2022 Apr; 19(7):. PubMed ID: 35410028
[TBL] [Abstract][Full Text] [Related]
2. The Role of Galectin-3 in Predicting Congenital Heart Disease Outcome: A Review of the Literature.
Făgărășan A; Săsăran M; Gozar L; Crauciuc A; Bănescu C
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445687
[TBL] [Abstract][Full Text] [Related]
3. Utility of galectin-3 as a prognostic biomarker in heart failure: where do we stand?
Srivatsan V; George M; Shanmugam E
Eur J Prev Cardiol; 2015 Sep; 22(9):1096-110. PubMed ID: 25268020
[TBL] [Abstract][Full Text] [Related]
4. [Impact of galectin 3 as myofibrosis marker in clinical cardiology].
Málek F
Vnitr Lek; 2014 Apr; 60(4):327-30. PubMed ID: 24985993
[TBL] [Abstract][Full Text] [Related]
5. Galectin-3 and heart failure: prognosis, prediction & clinical utility.
Filipe MD; Meijers WC; Rogier van der Velde A; de Boer RA
Clin Chim Acta; 2015 Mar; 443():48-56. PubMed ID: 25446877
[TBL] [Abstract][Full Text] [Related]
6. The Diagnostic and Therapeutic Potential of Galectin-3 in Cardiovascular Diseases.
Sygitowicz G; Maciejak-Jastrzębska A; Sitkiewicz D
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053194
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic and prognostic biomarkers reflective of cardiac remodelling in diabetes mellitus: A scoping review.
Chhor M; Law W; Pavlovic M; Aksentijevic D; McGrath K; McClements L
Diabet Med; 2023 May; 40(5):e15064. PubMed ID: 36782075
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of galectin-3 in adults with congenital heart disease.
Baggen VJM; van den Bosch AE; Eindhoven JA; Menting ME; Witsenburg M; Cuypers JAAE; Boersma E; Roos-Hesselink JW
Heart; 2018 Mar; 104(5):394-400. PubMed ID: 28942393
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of galectin-3 for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort.
Jagodzinski A; Havulinna AS; Appelbaum S; Zeller T; Jousilahti P; Skytte-Johanssen S; Hughes MF; Blankenberg S; Salomaa V
Int J Cardiol; 2015 Aug; 192():33-9. PubMed ID: 25985013
[TBL] [Abstract][Full Text] [Related]
10. Galectin-3 in cardiac remodeling and heart failure.
de Boer RA; Yu L; van Veldhuisen DJ
Curr Heart Fail Rep; 2010 Mar; 7(1):1-8. PubMed ID: 20425490
[TBL] [Abstract][Full Text] [Related]
11. Galectin-3 and HFpEF: Clarifying an Emerging Relationship.
Baccouche BM; Rhodenhiser E
Curr Cardiol Rev; 2023; 19(5):19-26. PubMed ID: 36959138
[TBL] [Abstract][Full Text] [Related]
12. Galectin-3 in Heart Failure: An Update of the Last 3 Years.
Gehlken C; Suthahar N; Meijers WC; de Boer RA
Heart Fail Clin; 2018 Jan; 14(1):75-92. PubMed ID: 29153203
[TBL] [Abstract][Full Text] [Related]
13. Acute cardiac dyspnea in the emergency department: diagnostic value of N-terminal prohormone of brain natriuretic peptide and galectin-3.
Stoica A; Şorodoc V; Lionte C; Jaba IM; Costache I; Anisie E; Tuchiluș C; Rusalim Petriș O; Sîrbu O; Jaba E; Ceasovschih A; Vâţă L; Şorodoc L
J Int Med Res; 2019 Jan; 47(1):159-172. PubMed ID: 30222016
[TBL] [Abstract][Full Text] [Related]
14. Can be galectin-3 a novel marker in determining mortality in hemodialysis patients?
Ozkan G; Ulusoy S; Menteşe A; Guvercin B; Karahan SC; Yavuz A; Altay DU; Ocal M
Clin Biochem; 2015 Aug; 48(12):768-73. PubMed ID: 25977067
[TBL] [Abstract][Full Text] [Related]
15. Plasma and Cardiac Galectin-3 in Patients With Heart Failure Reflects Both Inflammation and Fibrosis: Implications for Its Use as a Biomarker.
Besler C; Lang D; Urban D; Rommel KP; von Roeder M; Fengler K; Blazek S; Kandolf R; Klingel K; Thiele H; Linke A; Schuler G; Adams V; Lurz P
Circ Heart Fail; 2017 Mar; 10(3):. PubMed ID: 28288987
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of Galectin-3 for Adverse Outcomes in Chronic Heart Failure.
French B; Wang L; Ky B; Brandimarto J; Basuray A; Fang JC; Sweitzer NK; Cappola TP
J Card Fail; 2016 Apr; 22(4):256-62. PubMed ID: 26571149
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms responsible for increased circulating levels of galectin-3 in cardiomyopathy and heart failure.
Nguyen MN; Su Y; Vizi D; Fang L; Ellims AH; Zhao WB; Kiriazis H; Gao XM; Sadoshima J; Taylor AJ; McMullen JR; Dart AM; Kaye DM; Du XJ
Sci Rep; 2018 May; 8(1):8213. PubMed ID: 29844319
[TBL] [Abstract][Full Text] [Related]
18. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
[TBL] [Abstract][Full Text] [Related]
19. The usefulness of sST2 and galectin-3 as novel biomarkers for better risk stratification in hypertrophic cardiomyopathy.
Gawor M; Śpiewak M; Janas J; Kożuch K; Wróbel A; Mazurkiewicz Ł; Baranowski R; Marczak M; Grzybowski J
Kardiol Pol; 2017; 75(10):997-1004. PubMed ID: 28612913
[TBL] [Abstract][Full Text] [Related]
20. Galectin-3: a new biomarker for the diagnosis, analysis and prognosis of acute and chronic heart failure.
Hrynchyshyn N; Jourdain P; Desnos M; Diebold B; Funck F
Arch Cardiovasc Dis; 2013 Oct; 106(10):541-6. PubMed ID: 24090952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
